The significant outperformance of Viking Therapeutics in the market, as evidenced by its 50.33% annualized return over the past 5 years, suggests a strong positive momentum for the stock. This historical performance, coupled with a substantial increase in market capitalization to $7.38 billion, indicates a robust financial health and growth trajectory that could continue to attract investor interest in the short term.